daclatasvir was approved in europe, for genotypes 1,3,and 4. daclatasvir and sovaldi together had the highest cure rate of any hep c combo tested. but they were halted due to splitting profits. it is released with asunaprevir, a protease inhibitor(ns3a). this gives europe another all oral option. not the best all oral tx, but much better then int/rib.
more countries were announced for generic sovaldi;
india
south africa
pakistan
egypt
indonesia
vietnam
mongolia
emerging markets such as china, brazil , that are considered middle class nations probably wont make the cut.